Cancer regression in patients after transfer of genetically engineered lymphocytes - Wikidata - thesis-toulmin - TriplyDB

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression in patients after transfer of genetically engineered lymphocytes

http://www.wikidata.org/entity/Q24654976

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Microchip platforms for multiplex single-cell functional proteomics with applications to immunology and cancer research miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy Focus on adoptive T cell transfer trials in melanoma In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Eradication of melanomas by targeted elimination of a minor subset of tumor cells Lentiviral vectors in gene therapy: their current status and future potential MicroRNAs in immune regulation--opportunities for cancer immunotherapy T cell receptor gene therapy for cancer Genetic engineering of T cells for adoptive immunotherapy Adoptive cell transfer: a clinical path to effective cancer immunotherapy Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Adoptive T cell therapy for cancer in the clinic Clinical development of gene therapy: results and lessons from recent successes Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Overview of current immunotherapeutic strategies for glioma The Evolution of T-cell Therapies for Solid Malignancies T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Acquired and intrinsic resistance in cancer immunotherapy CARs in chronic lymphocytic leukemia -- ready to drive Progress and prospects for engineered T cell therapies The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy Genetically modified T cells for the treatment of malignant disease Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond Immune reconstitution in chronic lymphocytic leukemia Gene therapy for skin diseases Genetic engineering with T cell receptors Optimal management of metastatic melanoma: current strategies and future directions Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Recent advance in antigen-specific immunotherapy for acute myeloid leukemia Understanding high endothelial venules: Lessons for cancer immunology Adoptive T-cell therapy for Leukemia Adoptive cell therapy for sarcoma

P2860

Q21131200-A692E7BC-9F47-47A2-8F20-91AC4F726C0D Q21183961-65360133-A5F8-4479-B347-05BDFA8CFD6D Q21245464-79662603-18FF-4C1D-91F6-2E2AD5F8AE62 Q21328679-047C415C-CC7C-4B9A-9CC5-651469DEC5DB Q21559398-0B370FB3-82A5-4487-A342-5BB6D837FA07 Q24596055-4E21D5BE-DED5-4424-8045-A1F10915BEAF Q24623215-CA5AAB0D-F740-4967-89CC-C6D4D9D19126 Q24624761-061226EA-3249-4359-B30D-2165850890A2 Q24629462-7F1E5E92-073A-4A0E-A5A4-6F3EC8AB25CF Q24631617-DE6C682E-E92E-4A63-BF03-70D02F456C87 Q24634774-414965CD-2A8F-44CE-BB5D-90C59A8B4096 Q24642718-EC092F05-494B-448A-B14C-2073D64B2340 Q24644774-5F90471A-07E6-4A8E-9085-22A21F13A692 Q24647124-9442A24E-4893-4C1A-9CB6-70F7E75C803B Q24651232-C61964CD-FC81-4624-83A4-E08DD113CCEA Q24680405-26ED108C-8230-4F0D-8947-BA5474A7BA3B Q26743393-DE7E60F9-471C-4C79-98AA-F51226C8871F Q26745444-7C179924-60F0-4EE5-A743-7C5EB92BC6A7 Q26774462-7F609756-A1E7-49C2-8C00-1B119917431B Q26774669-D8E13A25-E234-4A3C-B586-670C27E84281 Q26775720-FBB17028-8557-41C2-9B11-CA908DE0C2FD Q26776345-A082B771-B99B-4D3C-9A43-7875426DF57C Q26799372-9E01671B-5328-4377-8198-F421403962C3 Q26826830-28C5561D-2327-469A-9113-59CB3124737D Q26827701-A917A44A-5F50-4E6E-9E37-4A38CDBBB57D Q26830526-70642862-4F78-4997-8014-1A4488A5252A Q26852923-D0EC014A-D0CC-4C24-AD99-B9591E64CAC3 Q26859775-352D1F91-0235-4C57-8618-59A559E40477 Q26860657-D78E0E6B-ACAE-463D-890A-9753DD29A9E5 Q26861563-CB3AE5E4-168A-4F15-A6DD-A3053537A324 Q26865561-460BFAD4-3AF2-4915-8DE8-90003266BAE1 Q26994703-AF1A2162-1429-400A-B54D-30FACB03D1A4 Q26995677-1807F9FC-C073-4A04-89A1-98DC20AB3E28 Q26997338-97CF6784-1349-4B9F-8C04-CFD4365AC7D7 Q27002575-8874FAD8-F4A5-491B-BACF-4762470A62BF Q27004178-118A18FE-83AA-44B5-A415-A10181FC8F2D Q27005765-ECF34AC9-CB05-4A2F-AD49-8CC1EC9F6457 Q27005794-09A9EC70-FCF2-4D10-8413-3D9AA0999E2B Q27006934-B0EE11DB-F7F9-4277-8227-B8D8B4B7BBEB Q27009541-1CE7CF07-C790-4361-8E5F-69798E2FBCBE

P2860

Cancer regression in patients after transfer of genetically engineered lymphocytes

http://www.wikidata.org/entity/Q24654976

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Cancer regression in patients after transfer of genetically engineered lymphocytes

@ast

Cancer regression in patients after transfer of genetically engineered lymphocytes

@en

Cancer regression in patients after transfer of genetically engineered lymphocytes

@nl

type

label

Cancer regression in patients after transfer of genetically engineered lymphocytes

@ast

Cancer regression in patients after transfer of genetically engineered lymphocytes

@en

Cancer regression in patients after transfer of genetically engineered lymphocytes

@nl

prefLabel

Cancer regression in patients after transfer of genetically engineered lymphocytes

@ast

Cancer regression in patients after transfer of genetically engineered lymphocytes

@en

Cancer regression in patients after transfer of genetically engineered lymphocytes

@nl

P1433

Q24654976-D036BFAD-50C3-4413-89EA-E6AE93F624D0

P1476

Q24654976-985847D9-6B3B-4DE4-A5E9-9A733CA854E8

P2093

Q24654976-16D42A08-8CE1-4EC6-9C36-251A28812C02

Q24654976-1FC1423F-5F2C-4342-A045-16E31F9A8710

Q24654976-2B44EE3F-BE2E-49B0-AFFB-E1BE1801AC70

Q24654976-3B2B53A6-9611-4073-BD8E-F46BA02E9160

Q24654976-451389CF-B398-4586-8C72-E5309C38B7C0

Q24654976-6A7738D9-3206-4A55-83A2-F698C9535AAC

Q24654976-6DE75C69-76EC-4F4E-855A-5ECEB7659F41

Q24654976-91D0A84A-7F37-481E-B506-730ECE9B6967

Q24654976-A57CCBF5-DD73-431C-A264-8491445A1EC6

Q24654976-A9884ED1-1EF0-449B-9054-CBD575671BA0

P2860

Q24654976-1B9158A3-DDEA-45F5-987F-362C1E123291

Q24654976-34E8F374-AE27-4860-A9C0-F0D051D29A90

Q24654976-3D56DFB1-AA21-412A-88C1-D464CF32382F

Q24654976-485C0253-F08F-4AC1-AC7C-41AE70D1BC08

Q24654976-48DA4AA0-CDF7-4009-9841-8754944A0321

Q24654976-4E156714-D495-44B8-B109-126546E060C2

Q24654976-5A52B545-838B-4B85-B0AD-88D06B9F5B06

Q24654976-6B3E2440-AE5B-4C38-B632-65AAE8894EC0

Q24654976-73D96099-5200-41CB-B475-A7BED418E403

Q24654976-7EE01975-3056-4393-BE16-96E101DB94C5

P304

Q24654976-2EAE0772-BFA6-4915-B1FE-0685A4D17C8E

P31

Q24654976-77A5EC94-4962-42A3-A27F-57338F51B15A

P3181

Q24654976-BC678043-FA35-4062-9462-F6D8A009A5D2

P356

Q24654976-FA51E2C7-CE82-4261-A28F-1C3CC8B1ED91

P407

Q24654976-41AA57DA-F366-46A7-AC1C-AEF4C489C69B

P433

Q24654976-9DB99830-1C71-4D48-8B82-A54FD6896BE8

P478

Q24654976-255DCBFA-848D-4659-8A34-7FE127AF2387

P50

Q24654976-6B28CD49-5CCA-4226-BC72-A516F17FFEAD

P577

Q24654976-42F04ACE-B07C-4754-BDD8-EF3D76598503

P5875

Q24654976-5F04A098-6764-4404-8010-C4A7107A6614

P698

Q24654976-1E155CB5-93D7-4EF2-A47B-824861A279B4

P921

Q24654976-3CD3C792-CAF6-4FAB-988E-F8E4B6D5C52D

P932

Q24654976-177078FD-9648-4364-B303-B7B9F24C1203

P3181

P356

SCIENCE.1129003

P1433

P1476

Cancer regression in patients after transfer of genetically engineered lymphocytes

@en

P2093

Azam Nahvi

http://www.w3.org/2001/XMLSchema#string

Christiaan R de Vries

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

John R Wunderlich

http://www.w3.org/2001/XMLSchema#string

Linda J Rogers-Freezer

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Richard E Royal

http://www.w3.org/2001/XMLSchema#string

Richard M Sherry

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A new era for cancer immunotherapy based on the genes that encode cancer antigens

Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.

Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

T-cell-receptor gene therapy.

Targeting tumours with genetically enhanced T lymphocytes.

P304

126-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

878720

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1129003

http://www.w3.org/2001/XMLSchema#string

P407

P433

5796

http://www.w3.org/2001/XMLSchema#string

P478

314

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2006-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6842953

http://www.w3.org/2001/XMLSchema#string

P698

16946036

http://www.w3.org/2001/XMLSchema#string

P921

P932

2267026

http://www.w3.org/2001/XMLSchema#string